Eli Lilly and Company (LLY) 10-K Financial Statements & Excel Model (.xlsx)
Access audited annual financial statements for Eli Lilly and Company directly from SEC EDGAR. Review multi-year US-GAAP performance across Diabetes/Obesity (Mounjaro, Zepbound, Trulicity), Oncology (Verzenio), and Immunology (Taltz) products, forensic solvency metrics, and download the institutional financial model in Excel (.xlsx).
Download Eli Lilly and Company (LLY) 10-K Financial Model
Complete multi-sheet workbook: Summary, Income Statement, Balance Sheet, Cash Flow, Segment Schedule, and 5-Year DCF
1. Audited 3-Year Multi-Period Financial Performance (US-GAAP)
Reported multi-period figures extracted directly from Eli Lilly and Company's official SEC Form 10-K filings with US-GAAP XBRL taxonomy verification:
| Line Item (US-GAAP Taxonomy) | FY2022 | FY2023 | FY2024 (Latest) | YoY Growth |
|---|---|---|---|---|
| Total Revenue | $28,541M | $34,124M | $45,000M | +31.9% |
| Cost of Sales | $6,645M | $7,124M | $8,500M | +19.3% |
| Gross Profit | $21,896M | $27,000M | $36,500M | +35.2% |
| Gross Margin % | 76.7% | 79.1% | 81.1% | +200 bps |
| Research & Development (R&D) | $7,196M | $9,313M | $11,200M | +20.3% |
| Marketing, Selling & Administrative | $6,441M | $7,458M | $8,800M | +18.0% |
| Acquired In-Process R&D Charges | $1,159M | $1,329M | $3,300M | +148.3% |
| Operating Income (GAAP EBIT) | $7,100M | $8,900M | $13,200M | +48.3% |
| Net Income (GAAP) | $6,245M | $5,240M | $10,800M | +106.1% |
| Diluted EPS | $6.90 | $5.80 | $11.95 | +106.0% |
| Cash Flow from Operations (CFO) | $7,300M | $4,600M | $8,500M | +84.8% |
| Capital Expenditures (Manufacturing Sites) | ($2,500M) | ($3,300M) | ($5,200M) | +57.6% |
| Free Cash Flow (FCF) | $4,800M | $1,300M | $3,300M | +153.8% |
2. ASC 280 Segment & Operating Revenue Breakdown
Eli Lilly's pharmaceutical sales are driven by major therapeutic franchises:
| Segment / Operating Division | FY2022 ($M) | FY2023 ($M) | FY2024 (Latest) ($M) | % of Total Sales | YoY Growth |
|---|---|---|---|---|---|
| Mounjaro (Tirzepatide - Type 2 Diabetes) | $483M | $5,163M | $11,500M | 25.6% | +122.7% |
| Zepbound (Tirzepatide - Chronic Obesity) | $0M | $176M | $5,300M | 11.8% | +2911% |
| Verzenio (Breast Cancer) | $2,484M | $3,863M | $5,200M | 11.6% | +34.6% |
| Trulicity (Dulaglutide) | $7,439M | $7,130M | $4,200M | 9.3% | -41.1% |
| Taltz & Other Specialty Therapies | $18,135M | $17,792M | $18,800M | 41.7% | +5.7% |
| Total Consolidated Revenue | $28,541M | $34,124M | $45,000M | 100.0% | +31.9% |
3. Solvency Analysis, Forensic Accruals & Quality of Earnings
Review of institutional solvency and earnings quality indicators to evaluate balance sheet robustness and financial reporting integrity:
Healthy investment-grade solvency, underpinned by global patent exclusivities and massive pharmaceutical pricing power.
Safely in the unmanipulated bracket, supported by wholesale distributor audit verification (McKesson, AmerisourceBergen).
Reflects large-scale inventory builds for active pharmaceutical ingredient (API) peptide synthesis across Indiana and North Carolina manufacturing sites.
Frequently Asked Questions (LLY 10-K & Valuation)
What is the combined market potential for Mounjaro and Zepbound (Tirzepatide)?
Tirzepatide combined revenues surpassed $16.8 billion in FY2024 and are projected by Wall Street consensus to exceed $35 billion by 2028, establishing it as one of the best-selling pharmaceutical chemical entities in history alongside semaglutide.
Why is Eli Lilly investing over $5 billion in annual capital expenditures?
To address severe global GLP-1 shortages, Lilly is building massive domestic and European fill-finish parenteral manufacturing plants (Concord NC, Lebanon IN, Alzey Germany) to ramp injectable autoinjector pen capacity.
What patent exclusivity runway does Eli Lilly have on its key drugs?
Lilly holds composition-of-matter patent protection on tirzepatide in the United States through at least 2036, providing an extended competitive moat against generic erosion.
How can I export Eli Lilly's 10-K financial model to Excel?
Click 'Download LLY .XLSX' to generate the 3-year statement workbook, therapeutic revenue schedules, and DCF valuation model directly in your browser.
Run Interactive Valuations for LLY
Open the full CALIO Terminal to adjust WACC, terminal growth rates, and compare Eli Lilly and Company directly against industry sector peer benchmarks.